Becton Dickinson and Co (NYSE:BDX) Position Reduced by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. lowered its position in shares of Becton Dickinson and Co (NYSE:BDX) by 10.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,347 shares of the medical instruments supplier’s stock after selling 635 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Becton Dickinson and were worth $1,281,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. HC Financial Advisors Inc. bought a new position in Becton Dickinson and in the 4th quarter valued at about $2,456,000. HL Financial Services LLC grew its position in shares of Becton Dickinson and by 5.3% during the 1st quarter. HL Financial Services LLC now owns 6,314 shares of the medical instruments supplier’s stock worth $1,368,000 after purchasing an additional 315 shares in the last quarter. Albert D Mason Inc. acquired a new position in shares of Becton Dickinson and during the 1st quarter worth approximately $454,000. FTB Advisors Inc. grew its position in shares of Becton Dickinson and by 110.1% during the 1st quarter. FTB Advisors Inc. now owns 1,143 shares of the medical instruments supplier’s stock worth $247,000 after purchasing an additional 599 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its position in shares of Becton Dickinson and by 6.0% during the 1st quarter. Daiwa Securities Group Inc. now owns 11,130 shares of the medical instruments supplier’s stock worth $2,412,000 after purchasing an additional 629 shares in the last quarter. 83.87% of the stock is owned by institutional investors and hedge funds.

BDX has been the topic of a number of analyst reports. KeyCorp restated a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. ValuEngine upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Royal Bank of Canada restated a “hold” rating and issued a $248.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. JPMorgan Chase & Co. raised shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target for the company in a research note on Thursday, June 21st. Finally, Citigroup lifted their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $246.53.

In related news, insider Alexandre Conroy sold 20,128 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $228.74, for a total transaction of $4,604,078.72. Following the completion of the transaction, the insider now owns 35,583 shares of the company’s stock, valued at $8,139,255.42. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.00% of the stock is currently owned by insiders.

BDX stock traded down $2.17 during mid-day trading on Friday, hitting $249.33. The company had a trading volume of 1,327,611 shares, compared to its average volume of 929,594. The firm has a market cap of $67.29 billion, a price-to-earnings ratio of 26.30, a P/E/G ratio of 1.71 and a beta of 1.13. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and Co has a 12 month low of $191.53 and a 12 month high of $253.77.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The company’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 earnings per share. analysts forecast that Becton Dickinson and Co will post 11.01 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Friday, September 7th will be paid a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, September 6th. This represents a $3.00 annualized dividend and a yield of 1.20%. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

See Also: NASDAQ Stock Market Explained

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply